It is important to bear in mind that the results from the reports published refer, in general, to intermediate end-points (such as viral load, transaminase normalization, etc.), though important, it has not been clearly studied how these intermediate results impact on significant clinical findings such as decrease in mortality, hepatocellular carcinoma or cirrhosis.